Protocol Ledger

NCT05195632 · Phase II · ACTIVE NOT RECRUITING

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05195632 sponsored by Pierre Fabre Medicament in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-02 Enrollment: 63 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05195632
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)63 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05195632
Protocol FieldVerified Registry Value
NCT IdentifierNCT05195632
Consolidated Lead SponsorPierre Fabre Medicament
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment63 participants (ACTUAL)
Registered Start Date2022-06-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05195632
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Xiangya Hospital Central South UniversityChangsha, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI